SCHEMBL5267478

SCHEMBL5267478

Cc1ccc(C(C)NCc2cc(C)ccc2C)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
TAAR1 Q96RJ0 1/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NR3C1 P04150 1/20 0.37
NR3C2 P08235 1/20 0.37
HSD17B10 Q99714 1/20 0.35
HIF1A Q16665 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADRB2 P07550 1/20 0.35
POLB P06746 1/20 0.35
TRPA1 O75762 1/20 0.34
LMNA P02545 1/20 0.34
CHRM1 P11229 1/20 0.34
SLC6A2 P23975 1/20 0.34
ADRA1A P35348 1/20 0.34
HTR2B P41595 1/20 0.34
GPR139 Q6DWJ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443358 0.89 ALDH1A1 (0.48) ALDH1A1KDM4ENPC1RAB9AHSD17B10
SCHEMBL5266655 0.82 HTR7 (0.40) ALDH1A1KDM4ETAAR1NPC1RAB9A
SCHEMBL5273044 0.82 POLB (0.41) ALDH1A1KDM4ETAAR1NPC1RAB9A
SCHEMBL5270099 0.82 ALDH1A1 (0.37) ALDH1A1KDM4ETAAR1NPC1RAB9A
SCHEMBL5268227 0.82 TP53 (0.41) ALDH1A1KDM4ERAB9APOLBLMNA
SCHEMBL5268202 0.82 TAAR1 (0.38) ALDH1A1KDM4ETAAR1NPC1RAB9A
SCHEMBL5267270 0.81 SMN1; SMN2 (0.54) ALDH1A1KDM4ESMN1; SMN2ADRB2POLB
SCHEMBL5269274 0.81 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10HIF1ASMN1; SMN2
SCHEMBL5268249 0.81 NPC1 (0.36) ALDH1A1KDM4ETAAR1NPC1RAB9A
SCHEMBL5272934 0.80 CASR (0.41) ALDH1A1KDM4ETAAR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074539-B1 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL CO (JP) 2007-10-17 EP disclosed
US-6894190-B2 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-17 US disclosed
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2003-12-18 US disclosed
US-6653507-B2 Useful intermediate compound of pharmaceuticals for urinary incontinence SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-11-25 US disclosed
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2002-10-03 US disclosed
US-6403832-B1 MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-11 US disclosed
EP-1074539-A2 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, CYP8B1, CYP11B2 ALDH1A1 141/4885KDM4E 3102/4885TAAR1 2567/4885
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, ALDH7A1, ALDH18A1 ALDH1A1 73/4885KDM4E 2234/4885TAAR1 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.